Market Cap | 602.11M | P/E | - | EPS this Y | -28.30% | Ern Qtrly Grth | - |
Income | -123.44M | Forward P/E | -3.74 | EPS next Y | -15.80% | 50D Avg Chg | 31.00% |
Sales | 33.11M | PEG | -0.08 | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 1.56 | EPS next 5Y | 14.50% | 52W High Chg | -46.00% |
Recommedations | 1.90 | Quick Ratio | 8.55 | Shares Outstanding | 90.36M | 52W Low Chg | 78.00% |
Insider Own | 9.93% | ROA | -24.49% | Shares Float | 81.46M | Beta | 2.29 |
Inst Own | 62.76% | ROE | -42.57% | Shares Shorted/Prior | 11.63M/11.52M | Price | 7.06 |
Gross Margin | -289.97% | Profit Margin | - | Avg. Volume | 3,073,053 | Target Price | 15.63 |
Oper. Margin | -1,255.80% | Earnings Date | - | Volume | 1,542,529 | Change | -3.42% |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
HC Wainwright & Co. | Buy | Sep 3, 24 |
HC Wainwright & Co. | Buy | Aug 14, 24 |
RBC Capital | Outperform | Aug 7, 24 |
HC Wainwright & Co. | Buy | Jul 17, 24 |
HC Wainwright & Co. | Buy | Jun 4, 24 |
Truist Securities | Buy | May 16, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
HC Wainwright & Co. | Buy | Mar 19, 24 |
RBC Capital | Outperform | Mar 12, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Haurwitz Rachel E. | President and CEO President and CEO | Mar 20 | Option | 2.96 | 10,000 | 29,600 | 30,000 | 03/22/23 |
Kanner Steven | Chief Scientific Off.. Chief Scientific Officer | Dec 02 | Option | 2.69 | 21,401 | 57,569 | 323,460 | 12/02/22 |
Kanner Steven | Chief Scientific Off.. Chief Scientific Officer | Aug 25 | Option | 2.69 | 43,248 | 116,337 | 345,307 | 08/26/22 |
Kanner Steven | Chief Scientific Off.. Chief Scientific Officer | Aug 25 | Sell | 11.22 | 43,248 | 485,243 | 302,059 | 08/26/22 |
Kanner Steven | Chief Scientific Off.. Chief Scientific Officer | May 13 | Option | 2.25 | 74,420 | 167,445 | 302,059 | 05/17/22 |
Haurwitz Rachel E. | President and CEO President and CEO | May 09 | Option | 2.96 | 10,000 | 29,600 | 20,000 | 05/10/22 |
Haurwitz Rachel E. | President and CEO President and CEO | Jan 26 | Option | 2.96 | 10,000 | 29,600 | 10,000 | 05/10/22 |
Fischesser Ryan | VP of Finance and Co.. VP of Finance and Controller | May 05 | Option | 3.4 | 2,274 | 7,732 | 115,518 | 05/06/22 |
Fischesser Ryan | VP of Finance and Co.. VP of Finance and Controller | Mar 15 | Option | 3.4 | 2,274 | 7,732 | 113,244 | 03/17/22 |
Kanner Steven | Chief Scientific Off.. Chief Scientific Officer | Mar 04 | Option | 3.4 | 10,720 | 36,448 | 227,639 | 03/07/22 |
O'Byrne Jason | Chief Financial Offi.. Chief Financial Officer | Feb 08 | Option | 4.11 | 24,336 | 100,021 | 24,336 | 02/08/22 |
Fischesser Ryan | VP of Finance and Co.. VP of Finance and Controller | Jan 11 | Buy | 3.4 | 7,387 | 25,116 | 109,082 | 01/12/22 |
MCCLUNG BARBARA G | Chief Legal Officer Chief Legal Officer | Oct 20 | Buy | 2.69 | 9,219 | 24,799 | 342,844 | 10/21/21 |
Kanner Steven | Chief Scientific Off.. Chief Scientific Officer | Oct 12 | Buy | 2.1 | 114,860 | 241,206 | 215,031 | 10/13/21 |